EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Azelastine Hydrochloride in Children with Perennial Allergic Rhinitis

Jean Bousquet, Ludger Klimek, Hans-Christian Kuhl, Duc Tung Nguyen, Rajesh Kumar Ramalingam, G Walter Canonica, William E Berger

International Archives of Allergy and Immunology · 2024

DOI: 10.1159/000542054 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift International Archives of Allergy and Immunology, 2024. Verfasst von Jean Bousquet und 6 weiteren Autor:innen. Beteiligte Einrichtung: Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Phthalazines, Rhinitis, Allergic, Perennial. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Allergic rhinitis (AR) affects up to 40% of the pediatric population. The US practice parameter recommends the use of intranasal antihistamines (INAH) or INCS as first-line therapy for the treatment of AR. Although not directly targeted to children, the recent US practice parameters proposed INAH as first-line therapy whereas the ARIA guidelines did not.

Methods

This was a randomized, double-blind, parallel-group study with a duration of 28 days. It compared azelastine hydrochloride (AZE) 0.10% and 0.15% to placebo of one spray per nostril twice daily in pediatric subjects with moderate-to-severe symptomatic perennial allergic rhinitis (PAR).

Results

A total of 486 subjects were included in the study. The change from baseline rTNSS was statistically significant for 0.15% AZE (p = 0.005) and 0.10% AZE (p = 0.015) versus placebo. Here, 0.15% AZE showed an LS mean change of −3.45 (20.2%) over the 28-day treatment period from a baseline value of 16.60 in rTNSS, and 0.10% AZE showed an LS mean change of −3.37 (20.5%) over the 28-day treatment period from a baseline value of 16.35 in rTNSS. Somnolence was reported by 1 patient in the 0.1% group and 1 placebo patient (both of mild severity and unlikely to be related to treatment). None of the patients reported fatigue.

Conclusions

Here, 0.15% AZE significantly improved the overall rTNSS compared with placebo over the 28-day study period. A 0.15% AZE was well tolerated in this study. Key Messages: It is essential to perform studies in school children (6–11 years). However, for INAH, few studies exist in SAR, and, to our knowledge, there are no studies in PAR. This study shows for the first time that the higher dose of AZE is safe and effective in school children with PAR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Allergic AgentsPhthalazinesRhinitis, Allergic, PerennialAdolescentChildFemaleHumansMaleAdministration, IntranasalDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

AzelastineDouble-blind placebo-controlled trialEfficacyPerennial rhinitisSafety

Substanzen

Anti-Allergic AgentsazelastinePhthalazines

Autor:innen und Institutionen

  • Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany.
  • Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Department of Otolaryngology, Head and Neck Surgery, Universitätsmedizin Mainz, Mainz, Germany.
  • Center for Rhinology and Allergology, Wiesbaden, Germany.
  • Biometrics, Meda Pharma GmbH & Co KG (A Viatris Company), Bad Homburg, Germany.
  • Global Clinical Sciences, MEDA Pharma GmbH & Co KG (A Viatris Company), Bad Homburg, Germany.

Zitieren

APA

Bousquet, J., Klimek, L., Kuhl, H. C., Nguyen, D. T., Ramalingam, R. K., Canonica, G. W., & Berger, W. E. (2024). Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Azelastine Hydrochloride in Children with Perennial Allergic Rhinitis. International Archives of Allergy and Immunology. https://doi.org/10.1159/000542054

Vancouver

Bousquet J, Klimek L, Kuhl HC, Nguyen DT, Ramalingam RK, Canonica GW, et al. Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Azelastine Hydrochloride in Children with Perennial Allergic Rhinitis. International Archives of Allergy and Immunology. 2024. doi:10.1159/000542054

BibTeX
@article{Bousquet2024,
  author = {Bousquet, Jean and Klimek, Ludger and Kuhl, Hans-Christian and Nguyen, Duc Tung and Ramalingam, Rajesh Kumar and Canonica, G Walter and Berger, William E},
  title = {Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Azelastine Hydrochloride in Children with Perennial Allergic Rhinitis},
  journal = {International Archives of Allergy and Immunology},
  year = {2024},
  doi = {10.1159/000542054}
}
Kostenlos starten →